Clients

Genprex, Inc.

Company Snapshot: Genprex, Inc.

GNPX
Last Change Volume High Low

Company Overview

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Client News

  1. Apr 12 2019 Genprex Featured in NetworkNewsAudio Broadcast on Potential Gene Therapy Treatment for Cancer
  2. Apr 12 2019 Genprex (GNPX) Featured in NetworkNewsAudio Broadcast Discussing Gene Therapy Programs on the Cusp of Curing the Incurable
  3. Apr 11 2019 Genprex (GNPX) Featured in NetworkNewsWire Publication about Revolutionary Gene Therapies
  4. Apr 11 2019 Genprex (GNPX) Featured in NetworkNewsWire Publication about Revolutionary Gene Therapies
  5. Apr 11 2019 Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Cancer and Gene Therapy Treatment